No Data
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Tengshengbo Pharmaceuticals made its first appearance at the 2024 American Association for the Study of Liver Diseases (AASLD) annual meeting to release the results of the combination of siRNA (Elebsiran) with PEG-IFNα compared to monotherapy with PEG-IFN
The 48-week treatment data from the ongoing Phase 2 ENSURE study clearly indicates that the combination of elebsiran and PEG-IFNα can provide more benefits, resulting in a higher functional cure rate. Multiple combination study data conducted by the company and its partners will continue to support the company's strategy of achieving functional HBV cure in a broader patient population through the correct combination treatment plan. Peking, china and Durham, north carolina, usa, November 19, 2024 /PRNewswire/ -- Tengsheng Bo Pharmaceutical Biotechnology Co., Ltd. ("Tengsheng Bo Pharmaceutical" or "the company",
BRII-B: 2024 Interim Report
Tengsheng Bo Medicine-B (02137) issued a total of 0.1955 million shares under the stock incentive plan on August 27th.
Tengsheng Boyao-B (02137) issued an announcement on August 16, 2024, based on the audited financial statements for the fiscal year ended June 2021...
Brii Biosciences Records Wider Loss in H1 on Nil Revenue
